CHIRON VITRASERT TIME TO PROGRESSION IS 194 DAYS IN PHASE III TRIAL; OPHTHALMIC IMPLANT RECOMMENDED FOR APPROVAL BY FDA ADVISORY COMMITTEE
Executive Summary
Chiron Vision's sterile intravitreal ganciclovir implant Vitrasert increases time to progression of cytomegalovirus retinitis by 112 days compared to I.V. ganciclovir, according to studies presented at FDA's Ophthalmic and Dermatologic Advisory Committee meeting Dec. 8.